S
Shelly A. McNeil
Researcher at Dalhousie University
Publications - 216
Citations - 9148
Shelly A. McNeil is an academic researcher from Dalhousie University. The author has contributed to research in topics: Vaccination & Influenza vaccine. The author has an hindex of 43, co-authored 206 publications receiving 7709 citations. Previous affiliations of Shelly A. McNeil include University of Michigan & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Anthony L. Cunningham,Himal Lal,Martina Kovac,Roman Chlibek,Shinn-Jang Hwang,Javier Díez-Domingo,Olivier Godeaux,Myron J. Levin,Janet E. McElhaney,Joan Puig-Barberà,C. Vanden Abeele,Timo Vesikari,Daisuke Watanabe,Toufik Zahaf,Anitta Ahonen,Eugene Athan,J. F. Barba-Gomez,Laura Campora,F. de Looze,H. J. Downey,Wayne Ghesquiere,Iris Gorfinkel,Tiina Korhonen,Edward M. F. Leung,Shelly A. McNeil,Lidia Oostvogels,Lars Rombo,Jan Smetana,Lily Yin Weckx,Wilfred W Yeo,Thomas C. Heineman +30 more
TL;DR: HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older.
Journal ArticleDOI
Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women
Linda Dodds,Shelly A. McNeil,Deshayne B. Fell,Victoria M. Allen,Ann Coombs,Jeffrey Scott,Noni E. MacDonald +6 more
TL;DR: The data support the recommendation that pregnant women with comorbidities should receive influenza vaccination regardless of their stage of pregnancy during the influenza season, and all pregnant women are likely to benefit from influenza vaccination.
Journal ArticleDOI
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years
Kenneth E. Schmader,Myron J. Levin,John W. Gnann,John W. Gnann,Shelly A. McNeil,Timo Vesikari,Robert F. Betts,Susan Keay,Jon E. Stek,Nickoya D. Bundick,Shu-Chih Su,Yanli Zhao,Xiaoming Li,Ivan S. F. Chan,Paula W. Annunziato,Janie Parrino +15 more
TL;DR: In subjects aged 50-59 years, the ZV significantly reduced the incidence of HZ and was well tolerated, with the difference primarily due to higher rates of injection-site AEs and headache.
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women
Simon Dobson,Shelly A. McNeil,Marc Dionne,Meena Dawar,Gina Ogilvie,Mel Krajden,Chantal Sauvageau,David W. Scheifele,Tobias R. Kollmann,Scott A. Halperin,Joanne M. Langley,Julie A. Bettinger +11 more
TL;DR: In this paper, the authors compared the effect of two and three doses of the quadrivalent human papillomavirus (HPV) vaccine to women who received three and six months of the vaccine within 6 months, respectively.
Journal ArticleDOI
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Simon Dobson,Shelly A. McNeil,Marc Dionne,Meena Dawar,Gina Ogilvie,Mel Krajden,Chantal Sauvageau,David W. Scheifele,Tobias R. Kollmann,Scott A. Halperin,Joanne M. Langley,Julie A. Bettinger,Joel Singer,Deborah Money,Dianne Miller,Monika Naus,Fawziah Marra,Eric W. Young +17 more
TL;DR: Among girls who received 2 doses of HPV vaccine 6 months apart, responses to HPV-16 and HPV-18 one month after the last dose were noninferior to those among young women who received 3 doses of the vaccine within 6 months.